These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 38726038)

  • 21. Differences between ketamine's short-term and long-term effects on brain circuitry in depression.
    Gass N; Becker R; Reinwald J; Cosa-Linan A; Sack M; Weber-Fahr W; Vollmayr B; Sartorius A
    Transl Psychiatry; 2019 Jun; 9(1):172. PubMed ID: 31253763
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial.
    Phillips JL; Norris S; Talbot J; Birmingham M; Hatchard T; Ortiz A; Owoeye O; Batten LA; Blier P
    Am J Psychiatry; 2019 May; 176(5):401-409. PubMed ID: 30922101
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of GRIN2B , GRIA1 , and BDNF Polymorphisms on the Therapeutic Action of Ketamine and Esketamine in Treatment-Resistant Depression Patients: Secondary Analysis From a Randomized Clinical Trial.
    Beanes G; Caliman-Fontes AT; Souza-Marques B; Silva HDS; Leal GC; Carneiro BA; Guerreiro-Costa LNF; Figueiredo AV; Figueiredo CAV; Lacerda ALT; Costa RDS; Quarantini LC
    Clin Neuropharmacol; 2022 Nov-Dec 01; 45(6):151-156. PubMed ID: 36093918
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Study protocol for Ketamine as an adjunctive therapy for major depression (2): a randomised controlled trial (KARMA-Dep [2]).
    Jelovac A; McCaffrey C; Terao M; Shanahan E; Mohamed E; Whooley E; McDonagh K; McDonogh S; Igoe A; Loughran O; Shackleton E; O'Neill C; McLoughlin DM
    BMC Psychiatry; 2023 Nov; 23(1):850. PubMed ID: 37974160
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder.
    Dean RL; Marquardt T; Hurducas C; Spyridi S; Barnes A; Smith R; Cowen PJ; McShane R; Hawton K; Malhi GS; Geddes J; Cipriani A
    Cochrane Database Syst Rev; 2021 Oct; 10(10):CD011611. PubMed ID: 34623633
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist.
    Machado-Vieira R; Yuan P; Brutsche N; DiazGranados N; Luckenbaugh D; Manji HK; Zarate CA
    J Clin Psychiatry; 2009 Dec; 70(12):1662-6. PubMed ID: 19744406
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression.
    Zheng W; Zhou YL; Liu WJ; Wang CY; Zhan YN; Li HQ; Chen LJ; Li MD; Ning YP
    J Psychiatr Res; 2018 Nov; 106():61-68. PubMed ID: 30278319
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression.
    Acevedo-Diaz EE; Cavanaugh GW; Greenstein D; Kraus C; Kadriu B; Zarate CA; Park LT
    J Affect Disord; 2020 Feb; 263():568-575. PubMed ID: 31791675
    [TBL] [Abstract][Full Text] [Related]  

  • 29. What is the mechanism of Ketamine's rapid-onset antidepressant effect? A concise overview of the surprisingly large number of possibilities.
    Strasburger SE; Bhimani PM; Kaabe JH; Krysiak JT; Nanchanatt DL; Nguyen TN; Pough KA; Prince TA; Ramsey NS; Savsani KH; Scandlen L; Cavaretta MJ; Raffa RB
    J Clin Pharm Ther; 2017 Apr; 42(2):147-154. PubMed ID: 28111761
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ketamine and other glutamate receptor modulators for depression in adults.
    Caddy C; Amit BH; McCloud TL; Rendell JM; Furukawa TA; McShane R; Hawton K; Cipriani A
    Cochrane Database Syst Rev; 2015 Sep; (9):CD011612. PubMed ID: 26395901
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder.
    Niciu MJ; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Ballard ED; Brutsche NE; Furey ML; Zarate CA
    Int J Neuropsychopharmacol; 2014 Oct; 18(1):. PubMed ID: 25539512
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neural correlates of rapid antidepressant response to ketamine in bipolar disorder.
    Nugent AC; Diazgranados N; Carlson PJ; Ibrahim L; Luckenbaugh DA; Brutsche N; Herscovitch P; Drevets WC; Zarate CA
    Bipolar Disord; 2014 Mar; 16(2):119-28. PubMed ID: 24103187
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exploring Predictors of Ketamine Response in Adolescent Treatment-Resistant Depression.
    Lineham A; Avila-Quintero VJ; Bloch MH; Dwyer J
    J Child Adolesc Psychopharmacol; 2024 Mar; 34(2):73-79. PubMed ID: 38170185
    [No Abstract]   [Full Text] [Related]  

  • 34. A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression.
    Zarate CA; Mathews D; Ibrahim L; Chaves JF; Marquardt C; Ukoh I; Jolkovsky L; Brutsche NE; Smith MA; Luckenbaugh DA
    Biol Psychiatry; 2013 Aug; 74(4):257-64. PubMed ID: 23206319
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
    Murrough JW; Iosifescu DV; Chang LC; Al Jurdi RK; Green CE; Perez AM; Iqbal S; Pillemer S; Foulkes A; Shah A; Charney DS; Mathew SJ
    Am J Psychiatry; 2013 Oct; 170(10):1134-42. PubMed ID: 23982301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist.
    Phelps LE; Brutsche N; Moral JR; Luckenbaugh DA; Manji HK; Zarate CA
    Biol Psychiatry; 2009 Jan; 65(2):181-4. PubMed ID: 18996507
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of Early Ketamine Effects on Belief-Updating Biases in Patients With Treatment-Resistant Depression.
    Bottemanne H; Morlaas O; Claret A; Sharot T; Fossati P; Schmidt L
    JAMA Psychiatry; 2022 Nov; 79(11):1124-1132. PubMed ID: 36169969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
    Feder A; Parides MK; Murrough JW; Perez AM; Morgan JE; Saxena S; Kirkwood K; Aan Het Rot M; Lapidus KA; Wan LB; Iosifescu D; Charney DS
    JAMA Psychiatry; 2014 Jun; 71(6):681-8. PubMed ID: 24740528
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.
    Newport DJ; Carpenter LL; McDonald WM; Potash JB; Tohen M; Nemeroff CB;
    Am J Psychiatry; 2015 Oct; 172(10):950-66. PubMed ID: 26423481
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neural complexity EEG biomarkers of rapid and post-rapid ketamine effects in late-life treatment-resistant depression: a randomized control trial.
    Murphy N; Tamman AJF; Lijffijt M; Amarneh D; Iqbal S; Swann A; Averill LA; O'Brien B; Mathew SJ
    Neuropsychopharmacology; 2023 Oct; 48(11):1586-1593. PubMed ID: 37076582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.